BBH241220P178000
- 6.31
- 0.000.00%
VanEck Biotech ETF Newsroom
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Wednesday Ends With Index Decline | Wall Street Today
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regeneron Pharmaceuticals Unusual Options Activity
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025